What does Tarsus Pharmaceuticals, Inc. do?
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of…
What is Tarsus Pharmaceuticals, Inc.'s P/E and P/B ratio?
Tarsus Pharmaceuticals, Inc. has a P/E ratio of -66.7 and a P/B ratio of 9.73.
What is Tarsus Pharmaceuticals, Inc.'s debt-to-equity ratio?
Tarsus Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.26.
How much does Tarsus Pharmaceuticals, Inc. owe compared with what it owns?
Tarsus Pharmaceuticals, Inc. owes $0.43 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Tarsus Pharmaceuticals, Inc.'s Positivity rank?
Tarsus Pharmaceuticals, Inc. is ranked #5,825 of 6,774 companies globally and #3,242 of 4,000 in United States on PositoAI, with a Positivity Score of 14,983.
Does Tarsus Pharmaceuticals, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Tarsus Pharmaceuticals, Inc..
Where can I read the latest news about Tarsus Pharmaceuticals, Inc.?
Recent headlines about Tarsus Pharmaceuticals, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Tarsus Pharmaceuticals, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Tarsus Pharmaceuticals, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.